Invivyd, Inc. (IVVD) – What Are Investment Firms Saying About This Stock?

Posted by Stanley Muller on Oct 17th, 2026

Shares of Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) have been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.00.

A number of research analysts have weighed in on the stock. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Monday, September 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Invivyd in a research report on Thursday, August 27th. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, September 29th. Finally, Weiss Ratings upgraded shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th.

Check Out Our Latest Analysis on Invivyd

Invivyd Trading Down 7.5%

NASDAQ:IVVD traded down $0.05 on Friday, reaching $0.62. 3,450,516 shares of the stock traded hands, compared to its average volume of 7,816,278. The firm has a market capitalization of $182.34 million, a price-to-earnings ratio of -1.87 and a beta of 0.95. The company’s 50 day moving average is $0.82 and its 200-day moving average is $0.99. Invivyd has a 1-year low of $0.53 and a 1-year high of $3.07.

Invivyd (NASDAQ:IVVD – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. The business had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. On average, equities research analysts forecast that Invivyd will post -0.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jill Andersen sold 30,706 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $25,793.04. Following the completion of the transaction, the insider owned 283,774 shares in the company, valued at approximately $238,370.16. This represents a 9.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 228,024 shares of company stock worth $176,540 in the last 90 days. Company insiders own 12.25% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of IVVD. United Capital Financial Advisors LLC purchased a new position in Invivyd during the second quarter valued at approximately $84,000. Bank of America Corp DE purchased a new stake in Invivyd in the 2nd quarter worth approximately $311,000. Jupiter Topco LLC purchased a new stake in Invivyd in the 2nd quarter worth approximately $30,048,000. ADAR1 Capital Management LLC bought a new position in Invivyd in the 2nd quarter valued at $3,322,000. Finally, The Manufacturers Life Insurance Company bought a new position in Invivyd in the 2nd quarter valued at $52,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

About Invivyd

(Get Free Report)

Invivyd, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines designed to prevent and treat viral diseases. The company’s approach is intended to provide durable protection against rapidly evolving viruses by using engineered monoclonal antibodies that can be updated as pathogens change.

Invivyd’s leading product is pemivibart, marketed in the United States under the brand name PEMGARDA. The product received emergency use authorization from the U.S.